Clinical Trial Update: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase II trial (E-PRISM) evaluating elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma
• Smoldering Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Smoldering Myeloma, Smoldering Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2023-06-09